Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.

Autor: Zabriskie MS; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Vellore NA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Gantz KC; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Deininger MW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA., O'Hare T; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2015 Sep; Vol. 29 (9), pp. 1939-42. Date of Electronic Publication: 2015 Feb 13.
DOI: 10.1038/leu.2015.42
Databáze: MEDLINE